Clostridium difficile Infection: Is It Finally Time to Give Mom Vancomycin?

July 24, 2016 at 12:27 pm

Infectious Diseases in Clinical Practice July 2016 V.24 N.4 P.193–194

Editorial Comment

Gallagher, Jason C.

From the Department of Pharmacy Practice, School of Pharmacy, Temple University, Philadelphia, PA.

Despite the long-term availability of 2 primary and familiar options, the pharmacotherapy for Clostridium difficile infections (CDI) has evolved along an interesting path. Vancomycin enjoyed a time at the top of the armamentarium, though it was initially used due to the thought that Staphylococcus aureus was the cause of pseudomembranous colitis.1 When C. difficile was determined to be the true cause of disease in 1978, vancomycin was known to be active and had already demonstrated efficacy in the treatment of CDI.2 However, 2 primary factors prompted the search for a substitute therapy: the cost of commercially available oral vancomycin, and concerns that oral vancomycin use is associated with infection from vancomycin-resistant enterococci (VRE).3–5 From a microbiological, tolerance, and cost perspective, metronidazole was a logical choice……

abstract

http://journals.lww.com/infectdis/Fulltext/2016/07000/Clostridium_difficile_Infection__Is_It_Finally.1.aspx

PDF (CLIC in PDF)

Advertisements

Entry filed under: Antimicrobianos, Bacterias, Biología Molecular, Epidemiología, Health Care-Associated Infections, Infecciones gastrointestinales, Infecciones nosocomiales, Metodos diagnosticos, REPORTS, Sepsis, Update.

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases


Calendar

July 2016
M T W T F S S
« Jun   Aug »
 123
45678910
11121314151617
18192021222324
25262728293031

Most Recent Posts


%d bloggers like this: